The short version of TB-500 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-28 and is reviewed periodically as new material appears.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, EDAC or EDCI) is a water-soluble carbodiimide usually handled as the hydrochloride, which is a white solid. It is typically employed in the 4.0-6.0 pH range. It is generally used as a carboxyl activating agent for the coupling of primary amines to yield amide bonds. While other carbodiimides like dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIC) are also employed for this purpose, EDC has the advantage that the urea byproduct formed (often challenging to remove in the case of DCC or DIC) can be washed away from the amide product using dilute acid. Additionally, EDC can also be used to activate phosphate groups in order to form phosphomonoesters and phosphodiesters. Common uses for this carbodiimide include peptide synthesis, protein crosslinking to nucleic acids, but also in the preparation of immunoconjugates. EDC is often used in combination with N-hydroxysuccinimide (NHS) for the immobilisation of large biomolecules. Recent work has also used EDC to assess the structure state of uracil nucleobases in RNA.
Vampire: The Masquerade – Bloodlines was released on November 16, 2004, in competition with Half-Life 2, Metal Gear Solid 3: Snake Eater, Halo 2, and several other titles. Valve's contract for Troika's use of the Source engine guaranteed that Bloodlines could not be released before Half-Life 2 and could not be introduced to the public until after the announcement of Half-Life 2, over eighteen months after development began. In February 2004, the game was scheduled for release in spring 2005, partially to avoid competing with Half-Life 2 and the competitive Christmas period, before Activision moved the date to November 2004. Activision obtained model Erin Layne to play Jeanette in promotional material for the game. Layne worked with Bloodlines artist Tim Bradstreet for a day to provide the poses chosen by Activision to represent Jeanette in the game's posters, clothing, and other items. Despite generally favorable reviews, Bloodlines' initial release sold 72,000 copies and earned approximately US$3.4 million in sales, below Troika's other games, Arcanum: Of Steamworks and Magick Obscura (234,000 units, $8.8 million) and The Temple of Elemental Evil (128,000 units, $5.2 million). In comparison, Bloodlines' release competitor Half-Life 2 had sold 6.5 million copies by 2008. Bloodlines' relative failure contributed to the demise of Troika Games. Shortly after its debut, most development staff were laid off; the remaining staff tried to patch Bloodlines and develop game concepts to secure funding to keep Troika in business.
Rongliflozin/Olorigliflozin has been evaluated in phase I trials, but is not yet approved by the FDA Sergliflozin etabonate discontinued after phase II trials. Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Tofogliflozin, developed by Sanofi and Kowa Pharmaceutical, was approved in Japan in March 2014, under the brand names Apleway and Deberza. Velagliflozin, marketed as Senvelgo, produced by Boehringer Ingelheim Animal Health, was approved for use in diabetic cats in 2023.
It often continued to have shootouts with KMT/American spies along with bandits and assisted with protecting lumberjacks and logging facilities. The Forest Protection Police continued to use Cavalry, and were seen in photos with Mosin Nagant rifles. In the first few months of its founding, the Forest Protection Police lost many officers due to disorientation, and in October 1953, the Forest Protection Police began mapping forest regions of China and issuing crude maps to its officers. Due to the logistics issues of boots-on-the-ground firefighting, in 1960 the Forest Police received 122 paratroopers and founded the Forest Police Smokejumper Company (Chinese: 森警空降扑火中队) for rapid deployment against wildfires. The Lisunov Li-2 was used by the Smokejumper Company. On 27 May 1965 the Company saw its first action, deploying 10 Smokejumpers to assist with fighting a wildfire in Daxing'anling Prefecture. In 1978, the Smokejumper Company was renamed to the Airborne Detachment (Chinese: 森警机降支队). Between its establishment and 1981, the Airborne Detachment was deployed to fight a total of over 325 wildfires, however its fate past 1981 is currently unknown. On 18 April 1978, the Forest Police became a volunteer force with three years of service. On 3 May 1984, the Forest Police became part of the People's Armed Police and was under the dual command of the People's Armed Police and the National Forestry Administration. On 13 January 1988, the People's Armed Police Forestry Corps was officially established.
Sources: en.wikipedia.org
== Clinical significance == Haptotaxis plays a major role in the efficient healing of wounds. For example, when corneal integrity is compromised, epithelial cells quickly cover the damaged area by proliferation and migration (haptotaxis). In the corneal stroma, keratocytes within the wounded area undergo apoptosis, leaving the stroma devoid of cells that must be replaced. Keratocytes surrounding the wounded area proliferate and become fibroblasts that migrate to fill the wounded area. This creates a healthy environment with myofibroblasts and extracellular matrix. This is known as light backscattering or subepithial haze. When there is injury to an epithelial cell heptotaxis occurs, which is highly influenced by the cell's velocity, which is in turn influenced by direction of cell motility. Cells migrate easily and quickly in packs, so when one cell moves the rest follow in response to the gradient and initial cell movement. Mechanical effects like the buildup of tensile forces may play an important role for both division as well as motility of cells in tissue.
The Wound Man is a surgical diagram which first appeared in European medical manuscripts of the fourteenth and fifteenth centuries. The illustration acted as an annotated table of contents to guide the reader through various injuries and diseases whose related cures could be found on the text's nearby pages. The image first appeared in a printed book in 1491 when it was included in the Venetian Fasciculus medicinae, likely Europe's first printed medical miscellany. Thereafter it circulated widely in printed books until well into the seventeenth century. The Wound Man has since become a recognisable figure in popular culture.
=== Greek philosophy === In Ancient Greece, Aristotle remarked on the importance of semen: "For Aristotle, semen is the residue derived from nourishment, that is of blood, that has been highly concocted to the optimum temperature and substance. This can only be emitted by the male as only the male, by nature of his very being, has the requisite heat to concoct blood into semen." According to Aristotle, there is a direct connection between food and semen: "Sperms are the excretion of our food, or to put it more clearly, as the most perfect component of our food." The connection between food and physical growth, on the one hand, and semen, on the other, allows Aristotle to warn against "engag[ing] in sexual activity at too early an age ... [since] this will affect the growth of their bodies. Nourishment that would otherwise make the body grow is diverted to the production of semen.
Sources: en.wikipedia.org
== Causes == The underlying cause of the rapidly growing breast connective tissue, resulting in gigantic proportions, has not been well elucidated. However, proposed factors have included increased levels/expression of or heightened sensitivity to certain hormones (e.g., estrogen, progesterone, and prolactin) and/or growth factors (e.g., hepatocyte growth factor, insulin-like growth factor 1, and epidermal growth factor) in the breasts. Macromastic breasts are reported to be composed mainly of adipose and fibrous tissue, while glandular tissue remains essentially stable. Macromastia occurs in approximately half of women with aromatase excess syndrome (a condition of hyperestrogenism). Hyperprolactinaemia has been reported as a cause of some cases of macromastia. Macromastia has also been associated with hypercalcaemia (which is thought to be due to excessive production of parathyroid hormone-related protein) and, rarely, systemic lupus erythematosus and pseudoangiomatous stromal hyperplasia. It is also notable that approximately two-thirds of women with macromastia are obese. Aside from aromatase (as in aromatase excess syndrome), at least two other genetic mutations (one in PTEN, the other "MDNS" not yet located to gene level) have been implicated in causing macromastia. A handful of drugs have been associated with gigantomastia, including penicillamine, bucillamine, neothetazone, ciclosporin, indinavir, and prednisolone.
Surgery to attempt tumour removal is usually not possible or advisable for DIPG. By nature, these tumors invade diffusely throughout the brain stem, growing between normal nerve cells. Aggressive surgery would cause severe damage to neural structures vital for arm and leg movement, eye movement, swallowing, breathing, and even consciousness. A surgically performed brainstem biopsy for immunotyping of diffuse intrinsic pontine glioma has served a limited role in experimental clinical studies and treatment trials. However, recent studies have shown stereotactic needle biopsies can commonly be done safely and resulted in a histological diagnosis in 96.8% of cases. This has increased the frequency that biopsies have been used for diagnosis. This, however, is not the current standard of care for all patients, as it presents considerable risk depending on the biopsy location. The decision to do a biopsy is generally only done when medical imaging appears atypical enough that a different diagnosis is possible. Pontine biopsy is in no way a therapeutic or curative surgery, and the risks (potentially catastrophic and fatal) are only outweighed when the diagnosis is uncertain or the patient is enrolled in an approved clinical trial.
In 1881, Italian physicist Luigi Palmieri detected helium on Earth for the first time through its D3 spectral line, when he analyzed a material that had been sublimated during a recent eruption of Mount Vesuvius.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.